CRDF (Cardiff Oncology) Stock Based Compensation: $5.99 Mil (TTM As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $1.27
GF Value $1.43
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Stock Based Compensation?

Cardiff Oncology CRDF -7.58% 48 Stock Based Compensation is $5.99 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.43 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cardiff Oncology's Stock Based Compensation for the three months ended in Mar. 2026 was $1.66 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $5.99 Mil.

Cardiff Oncology Stock Based Compensation Related Terms

Cardiff Oncology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Stock Based Compensation Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.23 4.26 4.51 4.76 5.69

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.68 1.38 1.26 1.66
CRDF
48GF Score
Cardiff Oncology Inc CRDF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.99 Mil.

What does a Stock Based Compensation of $5.99 Mil mean?
Cardiff Oncology (CRDF) has a Stock Based Compensation of $5.99 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cardiff Oncology and its competitors.
Is Cardiff Oncology's Stock Based Compensation too high?
Cardiff Oncology's current Stock Based Compensation is $5.99 Mil. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Stock Based Compensation compare to MAIA and TELO?
Cardiff Oncology's Stock Based Compensation of $5.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cardiff Oncology and its competitors. Cardiff Oncology's current Stock Based Compensation is $5.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.43, compared to a current price of $1.27 — trading 11.5% below its estimated fair value. The current Stock Based Compensation is $5.99 Mil. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Stock Based Compensation is $5.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.27 is trading 11.5% below its estimated GF Value™ of $1.43. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Stock Based Compensation: $5.99 Mil
  • GF Value™: $1.43 vs. price of $1.27 (11.5% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27
Price
$1.43
GF Value